Review synthesizes preclinical and clinical evidence on Withaferin A’s effects on redox homeostasis in breast cancer, suggesting its therapeutic promise despite challenges.
, exerts multi-targeted anti-breast-cancer activity by modulating redox homeostasis, autophagy, and apoptosis. WA elevates reactive oxygen species, perturbs mitochondrial function, and suppresses NF-κB/STAT3 signaling, thereby inhibiting proliferation, epithelial-to-mesenchymal transition, metastasis, and breast cancer stem cell self-renewal. This review synthesizes preclinical and emerging clinical evidence from PubMed/MEDLINE, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov (January 2000-October 2025). Despite promising multi-pathway activity, limited oral bioavailability, model heterogeneity, and scarce human data hinder translation. Advanced nanoformulations and rigorously designed clinical trials are essential to realize WA's therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: